Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

1 Dividend Stock to Buy for Passive Income in 2023

Healthcare giant Johnson & Johnson (JNJ) has a six-decade-long history of consecutive dividend growth. So, given the uncertainties surrounding the market, this fundamentally strong dividend-paying stock might be an ideal buy now. Read more.

StockNews.com

Glasgow university spin-out secures £8.75 million for tennis elbow treatment trials

The business will use the new funds to advance development of its microRNA therapeutics

Insider UK

Queensland government announces pill testing trial at fixed and mobile sites

The government announces it is developing protocols around how the testing will operate, and is searching for a provider to trial at fixed and mobile locations in the state.

ABC News

From analysis to the latest developments in health,
read the most diverse news in one place.

The Next Generation Of Cancer Vaccines Is Coming; What That Means For Moderna And Other Biotech Stocks

Startling cancer vaccine results from Moderna could drive the company's second act and usher in the next big thing in biotech. Here's what you need to know.

Investors Business Daily

Bristol pharmacy tech firm grows workforce amid ‘deluge’ of demand

Titan PMR has developed a cloud-based software that helps pharmacies to manage medicine dispensing and control of business activities

Birmingham Post

The Covid Downfall Is Here: Moderna's Outlook Misses By More Than $2 Billion

Moderna stock toppled Thursday after missing guidance expectations by at least $2 billion as waning Covid shots champ at sales.

Investors Business Daily

1 Pharma Stock Poised for a Promising 2023

Following a year of solid growth in 2022, leading pharma company AstraZeneca’s (AZN) robust pipeline and recent launches look promising. Moreover, its strong fundamentals should enable the stock to deliver solid returns this year. So, AZN could be an ideal buy. Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

FDA expands contaminated eye product warning due to potential bacterial contamination, risk of blindness

The Food and Drug Administration is adding to a list of eye-care products consumers should stop using “immediately” over concerns of possible bacterial contamination that could lead to blindness if infection occurs.

Tribune News Service

Family of Henrietta Lacks asks court to reject Thermo Fisher’s second motion to dismiss lawsuit

BALTIMORE — Family members of Henrietta Lacks are asking a federal judge to reject Thermo Fisher Scientific’s second attempt to get the court to dismiss the family’s lawsuit against the multimillion-dollar biotech company.

Tribune News Service

3 Biotech Stocks to Buy and Hold for the Next 20 Years

The biotech industry is well-positioned for long-term growth owing to strong demand and continued breakthroughs. Furthermore, favorable government funding should boost the industry’s growth. Hence, it could be wise to buy and hold fundamentally sound biotech stocks Amgen (AMGN), Biogen (BIIB), and Amicus Therapeutics (FOLD) for the next two decades.…

StockNews.com

Fears of new 'zombie drug' which rots users' skin and could even lead to amputations

Animal sedative xylazine started being used on the streets of Puerto Rico but has recently been found in major cities in the US, and causes people's skin to rot off, requiring amputations

Daily Mirror

Apellis Surges To Four-Month High — Sending Rival Iveric Tumbling — On A First-Ever Approval

Apellis Pharmaceuticals snagged FDA approval for the first-ever geographic atrophy treatment, leading APLS stock to surge Tuesday.

Investors Business Daily

Harmony Biosciences, The No. 3 Biotech, Just Topped Forecasts; But Concerns Persist

Harmony Biosciences beat quarterly expectations Tuesday, but the biotech stock crumbled on a barrage of commercial concerns.

Investors Business Daily

Is Bristol-Myers a Good Dividend Stock to Pick up Right Now?

Leading pharma company Bristol-Myers Squibb’s (BMY) fiscal year 2022 revenue and EPS were in line with analysts’ estimates. While BMY continues to advance its innovative portfolio and pipeline, is it a good dividend stock to pick up right now? Read more to find out.

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Wales Online

Lateral flow test to detect pregnancy to go on sale in the UK

The SaliStick test kit is thought to be the first of its type in the world

Daily Mirror

World's first saliva test to tell if you're pregnant is coming to the UK

The SaliStick test kit was developed by Israeli start-up Salignostics and promises to deliver results in 10 minutes - and is similar to a lateral flow test for coronavirus

StockNews.com

1 Medical Stock to Buy in February and 1 to Avoid Like the Plague

The medical industry is expected to grow due to increasing healthcare requirements and federal support. Moreover, given the inelastic demand for healthcare products and services, fundamentally strong medical stock Nature's Sunshine Products (NATR) could be an ideal buy this month. However, SNDL (SNDL) might be best avoided, considering its weak…

StockNews.com

4 Pharma Stocks to Buy Now for the Long Haul

The pharma industry has experienced tremendous growth in recent years. The industry should continue to grow, driven by the growing market for personalized medicine and e-pharmacies. Hence, pharma stocks Pfizer (PFE), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and Zoetis (ZTS) might be worth buying for the long term. Also, these companies…

Get all your
news in one place.

100’s of premium titles.
One news app.

Evening Standard

New door-to-door pharmacy delivery app promises to make London life less painful

It’s like shopping at Boots on your phone with the meds biked to your home in minutes.

AAP

Pharmacy contraceptive pill trial a 'band-aid solution'

The health minister welcomes a proposed trial to allow pharmacists to prescribe the contraceptive pill but doctors' groups have criticised the move.

Investors Business Daily

Valneva Shares Topple As It Hits Ethics Roadblock With Pfizer In Lyme Disease Test

Valneva stock plummeted Friday after Pfizer said it will drop roughly half of the participants enrolled in their Lyme disease vaccine study.

StockNews.com

The 3 Best Pharma Stocks to Buy for Big Gains in 2023

The pharma industry witnessed solid growth amid the pandemic. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth over the coming years. Therefore, investors could consider buying fundamentally sound pharma stocks Johnson & Johnson (JNJ), AbbVie (ABBV), and…

Salon

The big business of clogged arteries

Medtronic, the world’s largest medical device company, allegedly "groomed" doctors to overuse its vascular products

The Independent UK

Moderna, Pfizer and BioNTech Covid vaccine patent dispute heads to 2024 trial

US firm Moderna is suing its competitors for alleged patent infringement in relation to their Comirnaty vaccine.

Investors Business Daily

Why Seattle Genetics, Alkermes Are Currently Outperforming Their Peers

Seattle Genetics and Alkermes beat fourth-quarter estimates Thursday, pushing Alkermes stock into a brief breakout as SGEN stock soared.

1 … 57 58 59 60

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.